Supreme Court Rejects Eli Lilly's Challenge to Whistleblower Law

• A federal jury found Lilly knowingly concealed retroactive drug price increases and failed to rebate Medicaid, resulting in $61 million in damages automatically tripled to $183 million under the False Claims Act
• The government recovered more than $6.8 billion through False Claims Act cases in fiscal 2025, with whistleblowers awarded over $330 million
• Lilly argued the law violates the Constitution by placing 'executive authority in the hands of private citizens with no meaningful supervision,' turning 'bounty hunters into ersatz executive officers'

Supreme Court Rejects Eli Lilly's Challenge to Whistleblower Law

Key Development:

The U.S. Supreme Court declined to hear Eli Lilly's constitutional challenge to the False Claims Act, upholding a $183 million judgment against the pharmaceutical company for defrauding Medicaid.

Case Details:

• The lawsuit stemmed from a 2014 whistleblower case brought by Ronald Streck, a lawyer and pharmacist
• A federal jury in 2022 found Lilly knowingly concealed retroactive price increases on certain drugs and failed to provide proper rebates to Medicaid
• Original damages of $61 million were automatically tripled to $183 million under the False Claims Act
• The 7th U.S. Circuit Court of Appeals upheld the verdict in 2025

Legal Background:

The False Claims Act, also known as "Lincoln's Law," was enacted in 1863 during the Civil War to combat fraud by defense contractors. The law was strengthened in 1986 and allows private individuals to sue on behalf of the federal government and share in recoveries.

Lilly's Argument:

The company argued the whistleblower provisions violate the Constitution by placing excessive federal executive power in the hands of private citizens without accountability to the president, essentially turning "bounty hunters into ersatz executive officers."

Market Implications:

• The ruling preserves a powerful enforcement mechanism against healthcare fraud
• U.S. government recovered over $6.8 billion in False Claims Act cases during fiscal year 2025
• Whistleblowers received more than $330 million in awards
• Decision maintains significant legal and financial risk for pharmaceutical companies and government contractors engaging in potentially fraudulent practices

The Supreme Court's refusal to hear the case reinforces the law's constitutional standing after 160+ years of use.